Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin

Objective: There are little data regarding safety and effectiveness of neoadjuvant chemotherapy (NACT) in patients who are considered unfit for receiving 3 weekly paclitaxel and carboplatin. The aim of this study was to examine the toxicity and response rates of weekly paclitaxel and carboplatin as...

Full description

Bibliographic Details
Main Authors: S B Dessai, S Chakraborty, T. V. S. Babu, S Nayanar, A Bhattacharjee, J Jones, S Balasubramanian, Vijay M Patil
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2016-01-01
Series:South Asian Journal of Cancer
Subjects:
Intolerable
metronomic
neoadjuvant chemotherapy
poor nutritional status
poor performance status
Online Access:http://journal.sajc.org/article.asp?issn=2278-330X;year=2016;volume=5;issue=2;spage=63;epage=66;aulast=Dessai

Internet

http://journal.sajc.org/article.asp?issn=2278-330X;year=2016;volume=5;issue=2;spage=63;epage=66;aulast=Dessai

Similar Items